Dual CDK4/6–PI3K/mTOR inhibition reinforces cytostatic programs and tumor control in preclinical models of primary and metastatic osteosarcoma

Osteosarcoma (OS) in pediatric, adolescent, and young adult (AYA) patients is an aggressive bone cancer with limited treatment options. Dysregulation of the CDK4/6–cyclin D axis and the PI3K/mTOR pathway contributes to OS pathogenesis, providing a biological rationale for co-targeting these signalin...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Farinaz Barghi, M. Reza Saadatzadeh, Erika A. Dobrota, Harlan E. Shannon, Barbara J. Bailey, Courtney Young, Rada Malko, Ryli Justice, Niknam Riyahi, Christopher Davis, Khadijeh Bijangi-Vishehsaraei, Keiko Kreklau, Lauren K. Stevens, Jenna Koenig, Shirzat Sulayman, Sheng Liu, Jun Wan, Melissa A. Trowbridge, Kathy Coy, Felicia M. Kennedy, Anthony L. Sinn, Marissa Just, Kyle W. Jackson, George Sandusky, L. Daniel Wurtz, Christopher D. Collier, Dana Mitchell, Emily E. Seiden, Edward M. Greenfield, Emma Doud, Amber Mosley, Steven P. Angus, Michael J. Ferguson, Pankita H. Pandya, Karen E. Pollok
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Elsevier 2026-02-01
Saila:	Neoplasia: An International Journal for Oncology Research
Gaiak:	Osteosarcoma CDK4/6 PI3K/mTOR Senescence Autophagy Preclinical models
Sarrera elektronikoa:	http://www.sciencedirect.com/science/article/pii/S1476558625001459
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!